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.2012.05.Abstract Non-alcoholic fatty liver disease (NAFLD) is a condition deﬁned by signiﬁcant lipid
accumulation (5–10%) in hepatic tissue in the absence of signiﬁcant chronic alcohol consumption.
We aim to detect frequency of fatty liver among overweight/obese adults and children and associ-
ated clinical; anthropological measures; biochemical; genetic and imaging studies. Eighty three con-
secutive adults and 72 children included in the study. All patients underwent clinical measurements
of height, body weight, body mass index (BMI), waist and hip circumference. Biochemical investi-
gations were done to all subjects including liver function tests; lipid proﬁle; fasting blood glucose;
insulin resistance (IR); high sensitivity C reactive protein (hs-CRP); adiponectin and genotyping of
adiponectin genes. Abdominal ultrasonography was done to search for fatty liver; to measure sub-
cutaneous fat thickness (SFT) and visceral fat thickness (VFT). Fatty liver was detected in 47
(65.3%) children and in 52 (62.7%) adults. Correlation analysis in both groups revealed that
enlarged liver was highly positively correlated to age; BMI, systolic blood pressure (SBP), diastolic
blood pressure (DBP); waist circumference; hip circumference, subcutaneous fat thickness (SFT)
and Visceral fat thickness (VFT), alanine aminotransferase (ALT), aspartate aminotransferase/ala-
nine aminotransferase (AST/ALT). In addition in adults to fasting blood glucose, cholesterol, tri-
glycerides (TG), low density lipoprotein (LDL), IR and hs-CRP. Homozygous T adiponectinarch Center, El bohooth St.,
20 201006063558.
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onal Research Center, Egypt.
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222 W.M. Ezzat et al.genotype at position +276 was signiﬁcantly increased among children with enlarged liver size and
hs-CRP. NAFLD affects a substantial portion of adults and children; it is associated with the met-
abolic syndrome.
ª 2012 Academy of Scientific Research & Technology. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a condition de-
ﬁned by signiﬁcant lipid accumulation (5–10%) in hepatic tissue
in the absence of signiﬁcant chronic alcohol consumption [1].
Most patients with NAFLD have increased liver fat content
alone (simple steatosis), but others develop increasing hepatic
inﬂammation known as nonalcoholic steatohepatitis (NASH),
and up to 20% of patients reveal progressive hepatic ﬁbrosis
and may eventually develop cirrhosis or liver failure [1,25].
The great majority of NAFLD occurs in the setting of so-
called metabolic syndrome (MS), in which insulin resistance
(IR) plays a key role [11]. The prevalence of MS (22%) and
of NAFLD (20%) in the general US population are amazingly
similar [7]. These observations support that primary NAFLD
is a hepatic complication of MS.
NAFLD is the most common cause of chronic liver disease,
constituting a major risk factor for progression to liver failure,
cirrhosis, and hepatocellular carcinoma [2,3,8]. Particularly
alarming are the data showing that NAFLD has become the
most common cause of liver disease in children [18].
The Third Report of National Cholesterol Education Pro-
gram (Adult Treatment Panel i; ATP i) provides a working
deﬁnition of metabolic syndrome (MS) [13] based on a combi-
nation of ﬁve categorical risk factors: central obesity, hyper-
tension, hypertriglyceridemia, low levels of HDL-cholesterol,
and hyperglycemia.
The importance of body fat topography to metabolic dis-
ease was ﬁrst recognized more than 60 years ago [1]. Subse-
quently, truncal obesity as measured by waist circumference
and the waist–hip ratio has been the focal point of most deﬁ-
nitions of the metabolic syndrome.
The pathophysiology of NAFLD is complex and available
data suggest that environmental factors such as diet, exercise,
and/or toxins [14] are likely to be important in its causation.
The echogenicity of the normal liver equals or minimally
exceeds that of the renal cortex or spleen. Intrahepatic vessels
are sharply demarcated, and posterior aspects of the liver are
well depicted. A genetic predisposition is indisputably present
in NAFLD, and several candidate genes affecting glucose and
lipid metabolism have been proposed [21].
Two common single-nucleotide polymorphisms (SNPs) in
exon/intron two of the adiponectin gene (45TG and 276GT)
have been associated with cardio-metabolic risk, with haplo-
types 45TT and 276GT/TT carrying a higher risk of type 2 dia-
betes and cardiovascular disease in cross-sectional and
prospective studies. Adiponectin enhances oxidation of free
fatty acid (FFA) and triglyceride-rich lipoprotein (TRLP)
metabolism independently of systemic inﬂammation or insulin
action [16]. The liver takes up circulating FFAs in a dose-
dependent fashion and low density lipoprotein (LDL) and
remnants through the LDL-receptor and the liver related
receptor protein (LRRP). Consistently, postprandial lipid stor-age contributes substantially to liver triglyceride (TG) pool in
NAFLD and the magnitude of postprandial lipemia correlated
with liver steatosis [29].
C-reactive protein (CRP) is an acute phase-reactant protein
synthesized by the liver that is also elevated in chronic inﬂam-
matory states. CRP levels have been shown to be closely related
to obesity, in particular central or visceral fat deposition. Ele-
vated serum hs-CRPwas reported to be a diagnostic tool or pre-
dictor of disease progression in patients with of NAFLD [26].
The aim of this study was to determine the frequency of
NAFLD in examined children and adults and the associated
clinical; biochemical; genetic and imaging investigations.2. Materials and methods
2.1. Patients
We performed a cross-sectional, proof of concept study on 83
consecutive adults and 72 children recruited from the liver,
pediatric clinics, Medical Service Unit, National Research
Center. Patients were enrolled in a study about new evidences
for obesity. The study protocol was approved by the Human
Ethics Committee of National Research Center, and written
informed consent was obtained. Children and adults of both
sexes were enrolled. Patients with any of the following criteria
were excluded from the study: hepatobiliary diseases, chronic
liver diseases including viral hepatitis malignancies, ascites,
medications known to cause hepatic steatosis (such as estro-
gens, corticosteroids, amiodarone, and valoprate; at present
or within the last 2 years), inﬂammatory bowel disease, human
immunodeﬁciency virus (HIV), chronic drug or alcohol abuse
(more than 20 g/day).
2.2. Anthropometric measurements and clinical examination
All patients underwent complete physical examination includ-
ing measurements of height, body weight, waist and hip cir-
cumference. Body mass index (BMI) was calculated
according to equation: BMI = weight (kg)/height2 (m).
Waist circumference (WC) was measured at the level mid-
way between the lowest rib margin and the iliac crest and
was plotted on American percentiles for waist circumference
[19]. Hip circumference was measured at the widest level over
the greater trochanters in a standing position by the same
examiner; then calculation of W/H ratio was done. Blood pres-
sure and heart rate were measured in the sitting position after
adequate resting time.
2.3. Laboratory measurements
Blood samples after 12 h fasting were collected from all indi-
viduals by a sterile venepuncture and are divided as follows:
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extraction using DNA extraction kits (QIAGEN). Three milli-
liters blood left in the tubes and allowed to clot for 30 min be-
fore centrifugation for 10 min then the sera separated from the
clotted samples are used for liver function tests (ALT, AST,
Albumin, Bil T and D, Alkaline Ph), lipid proﬁle (total choles-
terol, HDL, LDL, VLDL and triglycerides) and fasting glu-
cose were measured by Olympus AU 400 autoanalyser.
Insulin and serum high sensitivity C reactive protein CRP
(hs-CRP) were measured in immulite by chemiluminescence.
Insulin resistance was calculated by the homeostasis model
(HOMA-IR) using the following formula:
HOMA-IR = fasting insulin (mU/L) · plasma glucose
(mmol/L)/22.5 [20].
Adeponectin was measured by ELIZA technique.
2.4. Genotype analysis of adiponectin gene (two mutations)
Two milliliters blood in a tube containing EDTA to obtain a
complete hemogram stored at 80 C until analysis. Genomic
DNA was isolated from blood of overweight, obese individuals
and controls.
2.5. Extraction of DNA
This method is used for whole blood collected in Vacutainer
EDTA tubes. Use preferably the QIAamp Blood Kit (Cat. No.
51106; Qiagen Inc., Valencia, CA, http://www.qiagen.com.
The samples were equilibrated to room temperature.
a. Heat block was heated to 56 C.
b. Buffer AW1, Buffer AW2, and QIAGEN protease were
ensured that they had been prepared according to the
instructions.
c. All centrifugation steps should be carried out at room
temperature.
d. 200 ll of the whole blood yielded 3–12 lg of DNA.2.6. Procedure
1. 200 ll whole blood was added to 20 ll QIAGEN prote-
ase, and 200 ll Buffer AL into a 1.5 ml low binding
microcentrifuge tube (e.g., Cat. No. T6050G, Marsh
Biomedical Products, Rochester, NY). Mixed by
vortexing.
2. Incubated at 56 C for 10 min.
3. Spinned down brieﬂy to remove drops from the inside of
the tube.
4. 200 ll of 96–100% ethanol was added and mixed by
vortexing.
5. The mixture was carefully applied from step above to a
QIAamp spin column. Centrifuged 1 min at The QIA-
amp spin column was carefully opened and added full
speed (15,000g). The tube containing the ﬁltrate was dis-
carded. The DNA would be bound to the ﬁlters in the
spin columns. Column was placed in a clean 2 ml collec-
tion tube.
6. QIAamp spin column was opened and 500 ll Buffer
AW1 was added without hitting the rim. The cap was
closed and centrifuged 1 min at full speed. QIAamp spin
column was placed in a clean 2 ml collection tube.7. The QIAamp spin column was carefully opened and
added 500 ll Buffer AW2. The cap was closed and cen-
trifuged the QIAamp column for 3 min at maximum
speed.
8. The 2 ml collection tube containing the ﬁltrate was dis-
carded, the QIAamp spin column was placed in a new
collection tube and spinned for 1 min to remove residual
buffer AW2.
9. The spin column was placed in a clean 1.5 ml low bind-
ing microcentrifuge tube. Two hundred microliters Buf-
fer AE or distilled water was added to the spin column.
Incubated at room temperature for 5 min to elute the
DNA. Centrifuged 1 min at full speed. One microliters
of extracted DNA was used for a 50 ll PCR.
10. Stored at 4 C.
2.7. Genotyping
The adiponectin 45> G polymorphism was genotyped
by ampliﬁcation of genomic DNA using the following
primers: forward, 50- GAAGTAGACTCTGCTGAGATGG-
30; REVERSE, 50- TATCAGTGTAGGAGGTCTGTG
ATG-30. The product was digested with Sma1 (New England
BioLabs Inc.), and the digestion products were resolved by
electrophoresis in a 2% agarose gel. The adiponectin 276>
T polymorphism was genotyped by ampliﬁcation of genomic
DNA using the following primers: forward, 50- GGCCT
CTTTCATCACAGACC-30; reverse, 50-AGATGCAGCAA
AGCCAAAGT-30. The product was digested with Bsm1
(New England BioLabs Inc.), and the digestion products were
resolved by electrophoresis in a 2% agarose gel [5].
2.8. Ultrasound examination
In addition to the routine abdominal ultrasound examination
based on the clinical indication. Liver size was determined by
measuring distance between upper and lower borders in mid
clavicular line. Liver parenchyma was examined with sagittal
as well as longitudinal guidance of the probe and completed
by lateral and intercostals views. The examination of the liver
was carried out in dorsal recumbence and left lateral position
and in inspiration. The presence of steatosis was recognized as
a marked increase in hepatic echogenicity, poor penetration of
the posterior segment of the right lobe of the liver, and poor or
no visualization of the hepatic vessels and diaphragm. The li-
ver was assessed to be normal if the texture was homogeneous,
exhibited ﬁne-level echoes, or was minimally hyperechoic or
isoechoic compared with normal renal cortex, and if there
was no posterior attenuation of the ultrasound beam. Fatty li-
ver may be diagnosed if liver echogenicity exceeds that of renal
cortex and spleen and there is attenuation of the ultrasound
wave, loss of deﬁnition of the diaphragm, and poor delineation
of the intrahepatic architecture [17]. To avoid false-positive
interpretations, fatty liver should not be considered present if
only one or two of these criteria are fulﬁlled. Hepatomegaly
was deﬁned as a liver size above 155 mm measured as a subcos-
tal diameter in the midclavicular line. Transverse scanning was
performed to measure the maximum subcutaneous fat thick-
ness (SFT) and visceral fat thickness (VFT). Both measures
were obtained 1 cm above umbilicus in the midline of the
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was done without undue pressure that would alter the body
layer contour and thickness. SFT was deﬁned as the distance
between the external face of the rectoabdominal muscle and
the internal layer of the skin. VFT was deﬁned as the distance
between the anterior wall of the aorta and the internal layer of
the rectoabdominal muscle perpendicular to the aorta [23].
2.9. Statistical analysis
Data were expressed as mean ± SD and percentages. Mean
values between different groups were compared using one
way ANOVA test. X2 was used to study the pattern of distri-
bution of different variables. Correlations were performedTable 1 Clinical characteristics of the studied subjects.
Variables Children N= 72 Adults N= 83
Age(years) mean ± SD 10.8 ± 3.5 36.3 ± 13.3
Sex
Males no (%) 34 (47.2) 17(20.5)
Females no (%) 38 (52.8) 66 (79.5)
BMI (Wt/Ht2)
Average (20–25) no (%) 27 (37.5) 24 (28.91)
Overweight (25–30) no (%) 23 (31.9) 8 (9.63)
Obese (>30) no (%) 22 (30.6) 51 (61.45)
Waist C (cm) mean ± SD 87.0 ± 14.2 91.1 ± 19.3
Hip C (cm) mean ± SD 97.9 ± 17.8 112.2 ± 18.3
SFT (cm) mean ± SD 1.4 ± 0.5 1.5 ± 0.8
VFT(cm) mean ± SD 4.1 ± 1.8 3.1 ± 1.5
Liver
Normal no (%) 25(34.7) 31 (37.3)
NAFLD no (%) 47 (65.3) 52 (62.7)
Body mass index(BMI), waist circumference (Waist C), hip cir-
cumference (Hip C), subcutaneous fat thickness (SFT), visceral fat
thickness (VFT).
Table 2 Comparison between average, overweight and obese childr
Variables (mean ± SD) Average BMI(20–25) N= 27 Overweight BM
SBP mmHg 102.0 ± 8.2 101.6 ± 11.2
DBP mmHg 66.8 ± 6.5 64.5 ± 6.4
SFT (cm) 1.2 ± 0.2 1.4 ± 0.5
VFT (cm) 3.1 ± 1.4 3.6 ± 1.6
Cholesterol (mg/dl) 173.8 ± 29.5 169.3 ± 31.2
Triglycerides(mg/dl) 98.2 ± 31.3 104.5 ± 42.6
HDL (mg/dl) 40.7 ± 8.7 38.6 ± 6.9
LDL (mg/dl) 114.7 ± 28.1 124.6 ± 28.6
AST (IU/dl) 27.7 ± 11.7 23.4 ± 7.8
ALT IU/dl) 14.4 ± 9.8 13.8 ± 10.4
Adiponectin (lg/ml) 22.3 ± 33.1 23.5 ± 29.5
IR .11 ± .06 .18 ± .13
hs-CRP (mg/L) 1.8 ± 3.9 2.4 ± 4.4
Systolic blood pressure (SBP), diastolic blood pressure (DBP), subcutan
lipoprotein (HDL), low density lipoprotein (LDL), aspartate transaminas
sensitivity c reactive protein (hs-CRP).
NS: no signiﬁcant.
* p value is signiﬁcant.
** p value is highly signiﬁcant.with Pearson standard linear regression analysis. The SPSS
package for windows version 13 was used for the analysis.
p 6 0.05 was considered signiﬁcant, p< 0.001 was considered
highly signiﬁcant and p> 0.05 was considered insigniﬁcant.
3. Results
The baseline characteristics of the studied subjects are pre-
sented in Table 1. The mean age was10.8 (4–18) years in chil-
dren, while in adults it was 36.3 (18–60) years. Most of adults
were females79.5% while in children 52.8% were females.
Twenty four adults and 27 children have average body mass
index BMI (20–25) and they were considered as controls of
the study. Eight adults and 23 children were overweight BMI
(25–30) while obesity BMI (P30) was detected among 51
adults and 22 children. Fatty liver was detected in 47
(65.3%) children and in 52 (62.7%) adults.
In children, comparison between controls, overweight and
obese persons revealed that there were signiﬁcant differences
between them as regards age, systolic blood pressure (SBP),
subcutaneous fat thickness (SFT) and visceral fat thickness
(VFT) as shown in Table 2. In adults the same comparison re-
vealed that there were signiﬁcant differences between them as
regards all studied variables except high density lipoprotein
(HDL) as shown in Table 3.
We found that all fatty livers were enlarged with rounded
borders in children and adults. Fatty livers showed different
degrees of hyperechogenicity and blurred vasculatures. It was
noticed that the larger the liver the more echogenicity and
blurring of intrahepatic vasculatures.
Correlation analysis of liver size and the studied variables
revealed that the enlarged liver was positively correlated to
all variables except fasting blood glucose; lipids; adiponectin;
GOT and IR in children. It was found that enlarged liver
among children and adults was highly positively correlated
to age; BMI; SFT; VFT; waist circumference; hip circumfer-
ence; SBP and DBP (P= .000I). Moreover, in adults; the en-
larged liver was positively correlated to fasting blood glucose;en.
I (25–30) N= 23 Obese BMI (>30) N= 22 F P value
108.9 ± 18.1 3.954 .02*
70.3 ± 12.0 2.550 NS
1.8 ± 0.4 12.195 .0001**
5.3 ± 1.7 9.939 .0001**
168.7 ± 38.1 .223 NS
117.5 ± 57.1 1.534 NS
40.6 ± 8.4 .302 NS
112.9 ± 28.4 .695 NS
27.6 ± 28.1 .438 NS
22.1 ± 24.5 2.311 NS
24.8 ± 34.08 2.977 NS
.13 ± .19 2.977 NS
3.4 ± 5.4 1.091 NS
eous fat thickness (SFT), visceral fat thickness (VFT), high density
e (AST), alanine transaminase (ALT), insulin resistance (IR) and high
Table 4 Correlations between liver size, adiponectin and all
studied variables in children and adults.
Variables Children N= 72 Adults N= 83
r P value r P value
Age .585 .0001* .594 .0001**
BMI .350 .0001** .647 .0001*
SBP .468 .0001** .453 .0001**
DBP .315 .0001** .478 .0001**
Waist .431 .004* .663 .0001**
Hip .348 .02* .691 .0001*
Waist/hip .016 NS .276 .01*
SFT .520 .0001** .543 .0001**
VFT .310 .02* .707 .0001**
Fasting blood glucose .015 NS .284 .014*
Cholesterol .034 NS .361 .001*
Triglycerides .264 NS .360 .001*
HDL .237 NS .058 NS
LDL .163 NS .312 .007*
AST .129 NS .188 NS
ALT .284 .04* .323 .004*
AST/ALT .390 .0001** .128 NS
Adiponectin .097 NS .170 NS
IR .097 NS .262 .03*
hs-CRP .207 NS .321 .003*
Body mass index(BMI), systolic blood pressure (SBP), diastolic
blood pressure (DBP), subcutaneous fat thickness (SFT), visceral
fat thickness (VFT), high density lipoprotein (HDL), low density
lipoprotein (LDL), aspartate transaminase (AST), alanine trans-
aminase (ALT), insulin resistance (IR) and high sensitivity c reac-
tive protein (hs-CRP).
NS: no signiﬁcant.
* p value is signiﬁcant.
** p value is highly signiﬁcant.
Table 3 Comparison between average, overweight and obese adults.
Variables mean ± SD Average BMI (20–25) N= 24 Average BMI (20–25) N= 8 Average BMI (20–25) N= 51 F P value
SBP mmHg 107.9 ± 9.4 108 ± 6.0 121.6 ± 15.9 10.408 .0001**
DBP mmHg 69.7 ± 6.1 71.1 ± 3.3 78.8 ± 9.3 11.477 .0001**
SFT cm .9 ± .9 1.3 ± .4 1.8 ± .6 14.551 .0001**
VFT cm 1.7 ± .8 3.1 ± 1.0 3.8 ± 1.3 25.501 .0001**
Cholesterol (mg/dl) 176.9 ± 26.4 196.6 ± 34.9 219.0 ± 46.6 8.958 .001*
Triglycerides (mg/dl) 75.0 ± 31.4 97.6 ± 34.5 122.5 ± 62.8 6.507 .0022*
HDL (mg/dl) 44.5 ± 10.8 42.9 ± 11.7 45.3 ± 11.5 .192 NS
LDL (mg/dl) 118.0 ± 28.1 137.3 ± 25.9 149.1 ± 42.6 5.05 .011*
AST (IU/dl) 21.1 ± 10.1 20 ± 7.7 28.4 ± 23.3 1.4 NS
ALT (IU/dl) 9.3 ± 7.2 12 ± 5.9 20.6 ± 21.3 3.4 .0399*
Adiponectin lg/ml 45.13 ± 4.7 22.5 ± 12.4 10.04 ± 14.53 27.375 .0011*
IR 1.1±.88 1.1±.65 2.7 ± 2.7 5.006 .011*
hs-CRP (mg/L) 1.5 ± 1.4 6.8 ± 10.4 12.3 ± 18.0 4.173 .022*
Systolic blood pressure (SBP), diastolic blood pressure (DBP), subcutaneous fat thickness (SFT), visceral fat thickness (VFT), high density
lipoprotein (HDL), low density lipoprotein (LDL), aspartate transaminase (AST), alanine transaminase (ALT), insulin resistance (IR) and high
sensitivity c reactive protein (hs-CRP).
NS: no signiﬁcant.
* p value is signiﬁcant.
** p value is highly signiﬁcant.
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adults, it was found that mean values of hs-CRP was
11.7 ± 17.6 mg/L higher among subjects with fatty liver thanin persons with normal liver 3.8 ± 8.2 mg/L (P= .03,
signiﬁcant).
Genotyping analysis of adiponectin gene revealed that all
studied subjects have the common T/T genotype at position
+45 while adiponectin genotypes at position+276 was distrib-
uted among the subjects in form ofG/G,G/T andT/T. Compar-
ing the studied variables in relation to genotypes of adiponectin
gene +276 revealed that there was no signiﬁcant differences of
all variables in adults. On the other hand, among children there
were signiﬁcant differences as regards mean values of SBP, liver
size, adiponectin and hs-CRP as shown in Table 5.
4. Discussion
The sonographic picture of fatty liver was recorded in 65.3%
of children and in 62.7% of adults. These percentages were
high providing that all studied subjects were apparently
healthy. NAFLD is a health problem affecting Egyptian com-
munity. The size of this problem is not well determined. The
disease is so dangerous because it is what the National Insti-
tutes of Health refers to as a ‘‘silent disease’’ [30]. Non alco-
holic fatty liver disease develops over a long period of time,
but many people experience few, if any, symptoms until the
condition worsens to non alcoholic steatohepatitis (NASH)
or cirrhosis. This can explain why in our study children group
in contrast to adult one, liver size where signiﬁcant enlarged
while their laboratory parameters including FBG; lipid proﬁles
and IR still (in children) not affected as in adult, as this condi-
tion need long period to give its bad derangements.
This disease must not be ignored specially in our country;
Egypt is considered a highest endemic area for prevalence of
HCV infection. Liver steatosis or steatohepatitis represents a
co morbid condition that accelerates progression of chronicity;
morbidity and mortality among patients with chronic HCV
infection.
Fatty liver disease was found to be a component of meta-
bolic syndrome, especially in adults this was evidenced by
the signiﬁcant correlations between liver size and BMI; SBP;
Table 5 Laboratory investigations of subjects according to adiponectin genotype at position +276.
Variables mean ± SD In children In adults
G/G T/G+ T/T P value G/G T/G + T/T P value
Age (years) 13.0 ± 3.0 14.6 ± 5.3 NS 44.5 ± 8.6 40.2 ± 12.5 NS
SBP mmHg 111.6 ± 10.3 93.3 ± 5.8 .01 123.1 ± 17.5 121.2 ± 13.7 NS
DBP mmHg 69.2 ± 10.8 61.7 ± 12.6 NS 78.8 ± 9.4 78.6 ± 7.9 NS
Waist C (cm) 97.0 ± 17.8 94.5 ± 9.2 NS 98.4 ± 12.2 103.8 ± 15.8 NS
Hip C (cm) 104.3 ± 22.7 102.0 ± 14.1 NS 121.4 ± 10.4 119.1 ± 17.4 NS
FBS (mmol/L) 5.1 ± 0.5 5.5 ± 0.2 NS 5.6 ± 1.3 5.9 ± 2.6 NS
Cholesterol (mg/dl) 168.8 ± 32.9 209.3 ± 22.6 NS 217.4 ± 45.0 227.0 ± 42.6 NS
Triglycerides (mg/dl) 104.5 ± 34.8 145.0 ± 23.8 NS 115.9 ± 74.8 136.6 ± 64.2 NS
HDL (mg/dl) 43.2 ± 9.3 44.3 ± 15.6 NS 44.2 ± 7.5 42.6 ± 11.7 NS
LDL (mg/dl) 104.8 ± 27.0 136.0 ± 13.0 NS 146.6 ± 34.7 157.0 ± 34.7 NS
AST (IU/dl) 34.1 ± 35.3 27.3 ± 6.6 NS 25.0 ± 15.5 23.0 ± 9.4 NS
ALT (IU/dl) 27.9 ± 31.3 33.7 ± 26.3 NS 23.5 ± 15.8 19.9 ± 6.6 NS
hs-CRP (mg/L) 4.1 ± 5.0 12.6 ± 10.1 .03* 6.9 ± 9.2 11.9 ± 12.7 NS
Adiponectin lg/ml 26.7 ± 12.6 25.6 ± 11.0 .04* 22.4 ± 10.3 20.7 ± 9.6 NS
SFT (cm) 1.6 ± 0.6 2.1 ± 0.5 NS 2.1 ± 0.6 1.7 ± 0.6 NS
VFT (cm) 3.9 ± 2.0 3.7 ± 1.6 NS 4.3 ± 1.6 3.6 ± 1.1 NS
Liver (cm) 13.6 ± 0.4 15.6 ± 0.6 .01* 16.8 ± 1.0 16.5 ± 1.3 NS
Body mass index(BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), subcutaneous fat thickness (SFT), visceral fat thickness
(VFT), fasting blood sugar (FBS), high density lipoprotein (HDL), low density lipoprotein (LDL), aspartate transaminase (AST), alanine
transaminase (ALT), insulin resistance (IR) and high sensitivity c reactive protein (hs-CRP).
NS: no signiﬁcant.
* p value is signiﬁcant.
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ing blood glucose; IR; and lipids which are components of the
metabolic syndrome.
It was noticed that percentage of fatty liver among children
was more than that of obese children. This means that fatty li-
ver not only associated with overt obesity but also just over-
weight children can have enlarged liver. Abdominal adipose
tissue includes distinct anatomic depots, a subcutaneous fat de-
pot and an intraabdominal fat depot, which can be divided
into intraperitoneal and retroperitoneal depots [15]. The intra-
peritoneal fat depot, also known as visceral fat. Subcutaneous
fat differs from visceral fat in that venous drainage from sub-
cutaneous fat is directed into the systemic circulation, whereas
venous drainage from visceral fat is directed into the portal
vein. The metabolic products thus reach the liver directly
and exercise a ﬁrst-pass effect on liver metabolism [12,6]. It
has been hypothesized that visceral fat releases free fatty acids
and adipokines and thereby exposes the liver to fat accumula-
tion. It was found that size of liver in children was directly cor-
related to waist, hip circumferences, SFT and VF. This means
that we cannot depend on BMI only to deﬁne obese persons
but truncal obesity must be assessed to avoid associated prob-
lems like fatty liver disease.
Insulin resistance (IR) may be deﬁned as altered metabolic
condition in which higher than normal insulin levels are
needed to achieve normal metabolic responses or normal insu-
lin concentrations fail to achieve a normal metabolic response.
In the current study, it was found that insulin resistance was
directly correlated to liver size in adults but it was not corre-
lated to enlarged liver in children. Non-alcoholic fatty liver dis-
ease represents a continuum of hepatic injuries, which progress
from simple fatty liver (FL or HS) to hepatocellular ballooning
degeneration, formation of Mallory bodies and ﬁbrosis
(NASH). Previous studies suggested that pathogenesis of
NAFLD includes two hits: The ﬁrst hit involves accumulationof triacylglycerol (TAG) in hepatocytes. It has also been recog-
nized that HS in itself leads to hepatic IR by activating protein
kinase-theta (PKC-h) and Jun N-terminal kinase (JNK)
[28,10], which interfere with tyrosine phosphorylation of insu-
lin receptor substrate (IRS) IRS-1 and IRS-2 and impairs insu-
lin action in hepatocytes [22]. Steatosis and IR can cause and
potentiate each other creating a vicious cycle of metabolic dys-
function, so, we can ask which appears ﬁrst and can lead to the
other. This may explain why IR was not correlated to fatty li-
ver in children once the presence of hepatic steatosis is estab-
lished, progression to steatohepatitis involves a ‘second hit’
and oxidative stress is thought to play a key role as fatty liver
is more susceptible to oxidative injury [10].
Although hepatic fat accumulation, both in animals and in
humans, is strongly associated with a decrease in insulin sensi-
tivity, a large variability in this relationship exists that cannot
be explained by other parameters regulating insulin sensitivity
such as overall obesity, body fat distribution, or circulating
adipokines. In other words, for the same amount of hepatic
steatosis, subjects can be identiﬁed who have very high and
very low insulin resistance [28].
Unlike most adipocytokines, adiponectin is decreased in the
setting of obesity. Adiponectin is an antidiabetic hormone that
correlates with insulin sensitivity [9].
In the current study, we found that fatty liver was inversely
related to serum values of adiponectin, but this relation did not
reach the signiﬁcant value in adults. At the same time the fatty
liver was not correlated to adiponectin in children. This was
against previous studies which suggested that serum adiponec-
tin as well as hepatic gene expression of adiponectin and its
receptors are decreased and inversely related to the degree of
liver injury and they explained role of adiponectin in NAFLD
as adiponectin directly counteracts the effects of TNF-a on
insulin signaling and lipid metabolism [4]. Moreover, genotyp-
ing of adiponectin gene at position 45revealed that all subjects
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ical and biochemical parameters in relation of T/T, G/T and
G/G genotypes of adiponectin gene at position 267 revealed
no signiﬁcant differences among adults. On the other hand,
in children, mean values of SBP were signiﬁcantly higher in
relation to genotypes G/T and T/T than genotype G/G. mean
values of liver size were signiﬁcantly higher in relation to geno-
types G/T and T/T than genotype G/G. In accordance with
Musso and his colleagues found that the 45TT and 276GT/
TT genotypes were more prevalent in NAFLD patients than
in controls and independently predicted the severity of liver
disease in NASH [21].
In a study evaluating the validity of liver enzymes in
detecting persons with fatty liver, the sensitivity of alanine
aminotransferase(ALT) was higher than that of aspartate
aminotransferase (AST)and c glutamyl transferase (cGT)
[27]. This was conﬁrmed by our ﬁnding about ALT which
was signiﬁcantly correlated to size of the liver in children
and adults in agreement with study of Ruhl and Everhart,
who concluded that central adiposity, hyperleptinemia, and
hyperinsulinemia were the major determinants of the associa-
tion of overweight with elevated serum ALT activity [24].
We found that mean values of hs-CRP was signiﬁcantly
higher among cases with fatty liver disease. This was agreed
with study of Siramolpiwat et al., who concluded that serum
hsCRP is associated with NASH in patients with NAFLD.
And also can be use as non-invasive diagnostic and screening
test of NASH especially when combined with metabolic syn-
drome parameters [26].
The most widely accepted and most successful treatment for
fatty liver is dietary and lifestyle changes aimed at reducing fat
in the body. Many times, dietary changes are all that are
needed to reverse and control the condition [25].
5. Conclusion
NAFLD affects a substantial portion of adults and children; it
is associated with the metabolic syndrome, which includes
obesity, insulin resistance, hyperlipidemia, and hypertension.
NAFLD is emerging as one of the most common liver disor-
ders claiming urgent attention of the public, clinicians and
researchers. Obesity is an epidemic health disorder and
NAFLD can be a major health problem.
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